Pharma Bio Services (PBSV) AI Stock Analysis

• Market Cap: $13.28M
• Dividend Yield: N/A
• Average Volume (3M): 2.53K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.23
• Revenue Growth: -14.75%
• EPS Growth: 89.89%
• Country: US
• Employees: 75
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.01
• Shares Outstanding: 22,918,093
• 10 Day Avg. Volume: 1,930
• 30 Day Avg. Volume: 2,531
• PEG Ratio: 0.11
• Price to Book (P/B): 0.97
• Price to Sales (P/S): 1.40
• P/FCF Ratio: -18.34
• Enterprise Value/Market Cap: 0.25
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: <0.01
• Enterprise Value/Ebitda: -9.90
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: $0.50 ▼(-7.41% Downside)

Pharma Bio Services is facing significant financial challenges, with declining revenue and profitability being the most impactful factors. The technical analysis indicates bearish momentum, and the valuation is unattractive due to a negative P/E ratio. The company's strong balance sheet is a positive aspect, but liquidity issues and lack of profitability weigh heavily on the overall score.

Positive Factors

Strong Balance Sheet

A strong balance sheet with high equity and low leverage provides financial stability and reduces risk, supporting long-term operations.

Strategic Partnerships

Strategic partnerships enhance service offerings and market reach, potentially driving long-term revenue growth and competitive advantage.

EPS Growth

Significant EPS growth indicates improved profitability and operational efficiency, which can enhance investor confidence and support future growth.

Negative Factors

Declining Revenue

Declining revenue reflects potential market challenges and could impact the company's ability to invest in growth and innovation.

Negative Cash Flow

Negative cash flow highlights liquidity issues, which can limit the company's ability to fund operations and strategic initiatives long-term.

Low Profitability

Low profitability suggests challenges in cost management and pricing power, potentially affecting long-term financial health and competitiveness.

Pharma Bio Services Business Overview & Revenue Model

Company Description

Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company provides compliance consulting services to the pharmaceutical, chemical, biotechnology, medical device, cosmetic, food industries, and allied products companies in Puerto Rico, the United States, Europe, and Brazil. Its technical consulting services comprise regulatory compliance, validation, technology transfer, engineering, project management, and process support. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico.

How the Company Makes Money

PBSV generates revenue through a multi-faceted business model that includes service fees for clinical trial management, consulting services, and regulatory submissions. Key revenue streams consist of project-based contracts with pharmaceutical companies, retainer agreements for ongoing consulting services, and performance-based incentives tied to the successful completion of clinical trials. Additionally, PBSV has established strategic partnerships with research institutions and healthcare organizations, enhancing its service offerings and expanding its market reach, which further contributes to its financial performance.

Pharma Bio Services Financial Statement Overview

Summary

Pharma Bio Services faces significant challenges with declining revenue and profitability. The income statement shows a substantial decline in revenue and profitability, with a low net profit margin of 0.32%. The balance sheet is strong with a high equity ratio of 74.58%, indicating financial stability. However, the cash flow situation is concerning, with negative free cash flow and operating cash flow, highlighting liquidity issues.

Income Statement

The company shows a substantial decline in revenue and profitability. The TTM gross profit margin is 31.06%, indicating some efficiency in controlling production costs despite a negative EBIT and EBITDA margin. The net profit margin is low at 0.32%, reflecting weak profitability. Revenue growth is negative, suggesting challenges in maintaining sales levels.

Balance Sheet

Pharma Bio Services has a strong equity position with a high equity ratio of 74.58%, reflecting financial stability and low leverage. However, the debt-to-equity ratio is 0.01, indicating a low level of leverage which reduces financial risk. The company’s high stockholders' equity is a positive factor in its financial health.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow, indicating liquidity concerns. The operating cash flow to net income ratio is negative, highlighting inefficiencies in converting income into cash flows. Free cash flow shows no growth, suggesting potential cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.97B	9.51M	16.98M	19.40M	20.12M	21.56M
Gross Profit	576.58M	2.52M	5.07M	4.88M	5.36M	6.67M
EBITDA	-337.26K	-1.11M	1.31M	1.23M	-3.78M	2.38M
Net Income	-84.25K	-777.62K	1.31M	1.01M	-2.09M	2.05M
Balance Sheet
Total Assets	13.59B	16.29M	19.90M	20.65M	23.92M	29.92M
Cash, Cash Equivalents and Short-Term Investments	10.73B	12.75M	14.98M	14.46M	17.47M	17.14M
Total Debt	71.36M	194.03K	346.51K	487.36K	617.42K	2.79M
Total Liabilities	1.66B	2.58M	3.78M	4.09M	5.01M	7.20M
Stockholders Equity	11.93B	13.72M	16.13M	16.56M	18.91M	22.72M
Cash Flow
Free Cash Flow	235.71M	-726.44K	1.88M	573.19K	794.00K	1.47M
Operating Cash Flow	235.87M	-566.70K	1.89M	592.46K	804.84K	1.53M
Investing Cash Flow	1.63B	-1.36M	-4.22M	-19.27K	1.30M	-28.96K
Financing Cash Flow	-6.74M	-1.73M	-1.76M	-3.53M	-1.75M	193.68K

Pharma Bio Services Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.54
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PBSV, the sentiment is Negative. The current price of 0.54 is below the 20-day moving average (MA) of 0.56, below the 50-day MA of 0.56, and below the 200-day MA of 0.55, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.58 is Neutral, neither overbought nor oversold. The STOCH value of 14.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBSV.

Pharma Bio Services Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ZCMD	43 Neutral	$14.35M	-2.90	-8.96%	―	-24.64%	92.19%
PBSV	43 Neutral	$13.28M	-145.14	-0.66%	―	-14.75%	89.89%
HCTI	40 Underperform	$3.04M	>-0.01	-182.56%	―	-21.88%	68.40%
VSEE	38 Underperform	$14.04M	-0.52	―	―	187.24%	82.90%